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Abstract: Adrenal gland metastases are common in lung cancer. 
It is well recognized that aggressive treatment of solitary adre-
nal metastases leads to improved outcomes but the exact nature of 
adrenal deposits is not well understood. Controversy exists as to 
the routing of cancer cells to the adrenal gland with some believing 
that this transmission is lymphatic, in contrast to the more gener-
ally accepted theory of hematogenous spread. Recently published 
mathematical modeling of cancer progression strongly supports 
the lymphatic theory. With that in mind, we performed a literature 
review to look for biological plausibility of simulation results and 
believe that evidence supports the contention that metastases to 
the adrenal gland can be routed by means of lymphatic channels. 
This could explain improved survival for patients in whom soli-
tary adrenal metastases are managed aggressively with surgical or 
radiation modalities. We are calling for clinical trials prospectively 
testing this hypothesis.
Key Words: Non–small-cell lung cancer, Adrenal metastasis, 
Lymphatogenous spread.
(J Thorac Oncol. 2014;9: 442–446)
For over a century, metastases have been acknowledged to be unpredictable. White1 observed in his book Tumors in 
1913 that “We may have a carcinoma with extensive involve-
ment of the lymph glands and no visceral deposits, while we 
may find another similar carcinoma with extensive visceral 
tumors and no affection of the glands; or, again, we may find 
an extensive primary tumor without involvement of either 
glands or viscera.” Despite advancements in medical knowl-
edge, we have failed to quantify our understanding of meta-
static progression patterns. One example is the controversy in 
primary lung cancer and adrenal metastases. In lung cancer, 
although adrenal metastases are common, there is no clear 
consensus as to whether they occur by means of a lymphatic 
or hematogenous route. Perhaps because lung anatomy does 
not clearly reinforce connections of lymphatics between lungs 
and adrenals, many would regard these metastases as primar-
ily hematogenous. Although the lymphatic theory of adrenal 
gland spread is not novel as it was described by Onuigbo2 in 
1957, to date this finding is not usually acknowledged in clini-
cal practice. A recently published Markov chain–based math-
ematical model of metastatic progression of primary lung 
cancer supports the lymphatic pathway of spread.3,4 In this 
article, we briefly review the literature, discuss the new math-
ematical model of metastasis, and examine the strength of the 
evidence pointing to lymphatic connections between primary 
lung tumor and the adrenal gland. Proven correct, this would 
result in a down staging of this patient population to stage 
III and the related modification in treatment plan for curative 
intent.
MARKOV CHAIN MODEL’S CONFIRMATION OF 
LYMPHATIC ADRENAL SPREAD
The mathematical model,3,4 which we refer to as the 
“Newton” model, uses probabilistic methods such as Markov 
chain dynamics, random walkers, and Monte Carlo simula-
tions to simulate how a tumor cell moves from the primary 
tumor to each metastatic site. The model was generated by 
using an autopsy data set of 3827 untreated cancer victims.5 
For this report, we will focus on lung cancer as a primary site. 
The model regards metastasis-inducing cells as random walk-
ers on an anatomic network, each anatomic site serves as a 
node between which cells can travel to spread disease, the 
autopsy data set is treated as the steady-state distribution of 
metastasis, and computational strategies are used to identify 
the route and mean first-passage times (MFPT) by which can-
cer cells spread to arrive at the steady state. MFPT is a quan-
tity that tracks how many steps on average a random walker 
takes to reach a certain organ, starting from the primary site. 
The network makes no prior assumptions as to the connec-
tions between anatomic sites but uses the steady-state infor-
mation (autopsy data) to infer their values. Figure 1 shows 
the distribution of lung cancer metastases from the original 
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FIGURE 1. a, Metastatic tumor distribution for primary lung cancer from DiSibio and French data set: 163 primary lung cancer 
autopsies; 619 metastatic tumors; and 59 adrenal metastases. Histogram is normalized so that sum of areas is one. b, Mean 
first-passage times to other organs associated with a collection of random walkers leaving the primary lung tumor. Adrenal is 
the first visited site after LNs. Times are normalized so that regional LNs equal unity; others are scaled to it. c, Mean first-passage 
times to other organs associated with a collection of random walkers leaving the primary breast tumor. Adrenal is the seventh 
visited site. Times are normalized so that regional LNs equal unity; others are scaled to it. d, Mean first-passage times to other 
organs associated with a collection of random walkers leaving the primary colon tumor. Adrenal is the sixth visited site. Times 
are normalized so that regional LNs equal unity; others are scaled to it. e, Mean first-passage times to other organs associated 
with a collection of random walkers leaving the primary bladder tumor. Adrenal is the sixth visited site. Times are normalized so 
that regional LNs equal unity; others are scaled to it. f, Mean first-passage times to other organs associated with a collection of 
random walkers leaving the primary prostate tumor. Adrenal is the sixth visited site. Times are normalized so that regional LNs 
equal unity; others are scaled to it. LN, lymph node.
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autopsy data set and the relative ranking of metastatic sites 
based on the MFPT for five primary tumors. It is clear that 
in lung cancer, adrenal metastases occur relatively quickly 
(Figure 1b) compared with other metastatic sites. In lung can-
cer, the short passage times and relatively high transition prob-
abilities associated with adrenal metastases are in the range of 
what is typically seen for regional lymph node disease rather 
than for hematogenously spread sites. By comparison, adrenal 
metastasis in colon, breast, prostate, and other solid tumors 
(Figures 1c–f) do not share the short MFPT from the primary 
site to the adrenal.
LYMPHATIC THEORY OF ADRENAL GLAND 
METASTASIS IN PRIMARY LUNG CANCER
For one to accept a lymphatic theory of adrenal gland 
metastasis, several postulations need to be addressed. First, 
the presence of an anatomic connection between the primary 
tumor and the adrenal gland needs to be proven. Second, if 
those anatomic connections truly play a role in lung cancer 
metastasis, a preferential or earlier involvement of the adrenal 
gland on the ipsilateral side of the primary tumor should be 
seen. Lastly, patients with aggressively managed ipsilateral 
metastases should have improved outcomes. This is analo-
gous to improved outcome in patients with locoregional nodal 
spread compared with distant metastatic disease.
Anatomic Plausibility of Direct 
Lymphatic Connections
From the lung, direct lymphatic tributaries exist to the 
thoracic duct and to celiac and para-aortic nodes.6 This is 
confirmed by postmortem examination of coal miners show-
ing coal dust deposition in retroperitoneal lymph nodes in 
87% of cadavers suggesting a direct passage to the abdomen 
from lung.7
The thoracic duct is the main collecting lymphatic vessel 
of the chest, receiving lymphatic drainage from the abdominal 
viscera. The flow of lymph through the thoracic duct is unidi-
rectionally upward due to the lymphatic vessel valvular struc-
ture and smooth muscle in the vessel wall. However, if one in 
theory interrupts the typical upward lymph flow, the cancer 
cells can potentially travel caudad and reach the adrenal gland 
through those connections. In examining the entire lengths of 
the thoracic duct postmortem, Onuigbo8 found cancer cells in 
the thoracic duct in 62% of cases with the majority of cells 
clumping at the lymphatic valves, thus creating a potential for 
blockage. No human studies have looked at the flow direction 
in the thoracic duct in living cancer patients.
Incidence and Laterality of Adrenal 
Metastases in Non–Small-Cell Lung Cancer
Not surprisingly, there is an increase in the incidence 
of adrenal involvement as a patient’s disease progresses. 
Clinically isolated adrenal gland metastases discovered on 
staging computed tomography scans in patients otherwise 
presumed operable are rare in the pre–positron emission 
tomography (PET) era and are reported in 1.6% to 3.5% of 
non–small-cell lung cancer.9,10 The true number of adrenal 
metastases in this group is higher due to the poor ability of 
imaging technology to detect small tumor deposits. Matthews 
et al.11 and Finke et al.12 illustrated this point when reporting 
their autopsy series of patients dying within 1 month of cura-
tive lung resection. In their series, 3% to 7.6% of patients were 
discovered to have adrenal metastases on autopsy. Rates of 
adrenal involvement increase further to 9% in living metastatic 
cancer patients and to 25% to 39% in autopsy series.2,13–17
Unfortunately, laterality is rarely reported in surgical, 
radiation, or autopsy series. Out of 29 articles reviewed, only 
seven reported laterality.2,9–36 Only five provided data suf-
ficient to address the relevant question, and the majority of 
those had small numbers of patients and were retrospective. 
Porte et al.18 reported higher likelihood of ipsilateral involve-
ment, 72% versus 28% in patients with solitary adrenal 
metastases (n = 43, p < 0.01). Kocijancic et al.36 reported on 
patients with both unilateral and bilateral adrenal metastases 
and noted a 50% ipsilaterality (n = 50). The contralateral and 
bilateral disease was reported in conglomerate, and thus, it 
is not possible to estimate the difference between ipsilateral 
and contralateral involvement in this study. It is important to 
notice that the prevalence of ipsilateral involvement depends 
on the total burden of metastatic disease. If adrenal is the 
only site of metastasis, 50% of the metastases are ipsilateral. 
However, if adrenal metastases are present together with other 
sites, the typical ipsilaterality rate is numerically lower at 25% 
(p = 0.14). In addition, if patients initially operated for stage 
I–IIIA disease recur in the adrenal gland, 63% of recurrences 
are ipsilateral compared with 37% of contralateral or bilateral. 
This relationship is opposite in patients presenting with non-
operable cancers (IIIB or Iv) where incidence of ipsilateral 
disease is only 29% compared with 71% of contralateral/bilat-
eral ones (p = 0.034).36 Similar patterns are reported by Porte 
et al.9 who showed that patients with ipsilateral adrenal gland 
involvement have lower burden of systemic disease and are 
less likely to have other distant metastases than if contralateral 
adrenal gland is involved, at 20% versus 62%, respectively.
This increased incidence of ipsilateral involvement is 
also confirmed in a much larger autopsy series. In patients 
in whom adrenal metastasis was the only metastatic site, 
the ipsilateral adrenal gland is 1.59 times more likely to be 
involved than contralateral one (61% versus 39%, n = 405, 
p < 0.01). In patients with more than one metastatic site, ipsi-
lateral adrenal gland still consistently receives more metasta-
ses. This difference decreases as more metastatic sites develop 
and completely disappears in patients with six or more organs 
involved. In addition, bilateral adrenal metastases seem more 
common as disease progresses. For example, in a patient with 
four metastatic sites, the incidence of bilateral adrenal metas-
tases is approximately 60% compared with 5% if only two 
metastatic sites are discovered.17 Similar results were reported 
by Onuigbo2 who examined 1000 cadavers and reported 61% 
prevalence of ipsilateral involvement compared with 39% 
contralateral. As a composite, these data indicate that as can-
cer progresses and hematogenous pathways become definitely 
involved as indicated by other distant sites of spread, the like-
lihood of circulating tumor cells establishing metastases in 
the contralateral adrenal gland increases. It is possible that 
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in the beginning stages of metastasis, cancer could be reach-
ing the adrenal gland through the lymphatic channels before 
hematogenous metastases develop, thus explaining ipsilateral 
preponderance.
Differential Outcome in Aggressively 
Managed Ipsilateral versus 
Contralateral Adrenal Metastases
If managed solely with chemotherapy, even isolated 
adrenal metastases progress to death with reported survival of 
only 6 to 9 months.10,27 No randomized clinical trials compared 
the survival outcome of surgically managed adrenal metasta-
ses versus chemotherapy treated ones. In a small retrospective 
case series by Luketich and Burt22 (n = 14), the median sur-
vival was 31 months for patients treated with chemotherapy 
followed by surgical resection of both primary mass and a 
solitary adrenal metastasis versus 8.5 in patients treated with 
chemotherapy alone (p = 0.03). Reported outcomes are bet-
ter with adrenalectomy and radiation therapy (16–31 mo) 
than medically treated metastatic disease (9–12 mo).10,18–
20,22,23,29,30,32 If involvement of the ipsilateral adrenal gland is 
lymphatic in origin, one should see improvement in survival if 
the adrenal metastasis is managed aggressively with surgery 
and radiation similar to an improved survival seen in patients 
with stage III disease compared with patients with stage Iv 
disease. The main challenge in looking at this question is that 
studies reporting outcomes of aggressively managed isolated 
adrenal metastases fail to report outcomes based on laterality. 
Two studies deserve mentioning. Porte et al. in the pre-PET 
era showed that after resection of solitary adrenal metastases, 
recurrences are more common in patients with contralateral 
adrenal metastases than ipsilateral ones (n = 43, 83% versus 
77%, p > 0.05). Raz et al.27 compared survival outcomes based 
on the laterality of the metastasis in patients with aggressively 
managed adrenal metastases as defined by surgical resection 
together with resection of primary tumor. PET scan was not 
required but was performed in some patients, thus giving us a 
purer population in regard to undetected other distant metas-
tases. In a small cohort of patients (n = 20), they showed 
improvement in 5-year survival from 0% to 83% in contralat-
eral versus ipsilateral disease (p = 0.003).27
CONCLUSIONS
In summary, current models and a review of the litera-
ture suggest that there is a difference in prevalence and a pos-
sible difference in outcomes of patients with ipsilateral versus 
contralateral adrenal metastasis. Current guidelines such as 
those from the National Comprehensive Cancer Network, 
however, do not recommend discrimination in the treatment 
of adrenal metastasis based on laterality.
The last decade has seen the development of a num-
ber of improvements for the local therapy of metastatic dis-
ease, including the development of robotic assisted surgery 
and stereotactic radiotherapy. As these technologies reduce 
the burden of localized treatment of metastasis, it is critical 
that oncologists carefully define the populations that are most 
likely to benefit from interventions. Randomized, prospective 
clinical trials of surgical and other localized treatments will 
be difficult to complete in this relatively rare population. The 
creation of mathematical models may guide optimal anatomi-
cal sites for local therapy, but these models require clinical 
validation of their predictive ability. We would propose that 
large organizations such as the cooperative groups make an 
effort to create a nationwide registry of local therapy applied 
to oligometastatic patients. Such a registry should include 
surgical and radiosurgery-based approaches and could then 
be mined to compare the outcome with ipsilateral and con-
tralateral treatments of adrenal tumors and answer other 
questions that may be relevant to the oncology community. 
This approach may provide the kind of prospective data that 
would serve both to validate existing mathematical models of 
metastasis and to shape guidelines for the surgical manage-
ment of metastatic adrenal disease. If successful, this model-
ing and clinical validation strategy can be expanded to other 
tumor types.
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